Tonix OKd for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome

 TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating

Preclinical data show magnesium-potentiation increases the potency of exogenous oxytocin

Formulations of intranasal oxytocin without magnesium have reported inconsistent results in clinical trials of Prader Willi Syndrome

https://www.globenewswire.com/news-release/2023/12/04/2789891/28908/en/Tonix-Pharmaceuticals-Announces-IND-Clearance-by-the-FDA-for-Phase-2-Trial-of-TNX-2900-for-the-Treatment-of-Prader-Willi-Syndrome-the-Most-Common-Genetic-Cause-of-Life-Threatening-.html